The Efficacy Of EGFR-TKIs In The Patients With Advanced Non-small Cell Lung Cancer By Poor Performance Status:A Meta-analysis

Objective:The aim of this study is to analysis the available clinical data evaluating the efficacy of anti-EGFR therapies in patients with advanced NSCLC with poor performance status(PS≥2分).Methods:A literature-based meta-analysis of the results of randomized clinical trials about the anti-EGFR therapies in patients with advanced NSCLC was undertaken.Relevant publications from PubMed(1966-2017.5),the Cochrane Library(2017年第5期),Embase(1974-2017.5),wanfang data(1989-2017.5)and CNKI(1994-2017.5)were searched.Meta-analysis were performed by RevMan 5.3 software.Results:Totally 7 randomized clinical trials and 1954 were included.The Meta-analysis revealed an overall significant improvement in PFS(HR=0.42,95%CI 0.30–0.59;p<0.0001)with the use of EGFR TKIs in NSCLC.The data stratification per poor performance status subgroups showed that EGFR TKIs were more effective in prolonging PFS in patients with good performance status(HR=0.40,95%CI 0.25–0.64;p=0.0001),in comparison with patients with poor performance status(HR=0.63,95%CI 0.49–0.82;p=0.0005).Conclusion:The results of this study suggest that EGFR TKIs have a significant effect in slowing down diseases progression in patients with advanced NSCLC and poor performance status.